0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Neuroendocrine Carcinoma -Epidemiology Forecast to 2028
Published Date: March 2019
|
Report Code: DELV-Epid-124
Home | Market Reports | Health | Health Conditions | Cancer
Neuroendocrine Carcinoma Epidemiology Forecast to 2028

Neuroendocrine Carcinoma -Epidemiology Forecast to 2028

Code: DELV-Epid-124
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Neuroendocrine Carcinoma - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Neuroendocrine Carcinoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Neuroendocrine Carcinoma Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Neuroendocrine Carcinoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Neuroendocrine Carcinoma outlook. It also includes the explanation of changing trends of epidemiology outlining the Neuroendocrine Carcinoma scenario.

Neuroendocrine Carcinoma Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Neuroendocrine Carcinoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Neuroendocrine Carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Neuroendocrine Carcinoma Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Neuroendocrine Carcinoma

Key assessments
• Patient Segmentation in Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma Risk & Burden
• Factors driving growth in a specific Neuroendocrine Carcinoma patient population

1. Report Introduction
2. Neuroendocrine Carcinoma Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Neuroendocrine Carcinoma in 2016
2.2. Patient Share Distribution of Neuroendocrine Carcinoma in 2028
3. Disease Background and Overview: Neuroendocrine Carcinoma
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Neuroendocrine Carcinoma in 7MM
4.3. Total Prevalent/ Incident Patient Population of Neuroendocrine Carcinoma in 7MM – By Countries
5. Epidemiology of Neuroendocrine Carcinoma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.1.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma *
5.1.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.1.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.4.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.4.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.4.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.5.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.5.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.5.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.6.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.6.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.6.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.7.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.7.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.7.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.8.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.8.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.8.5. Diagnosed Cases of the Neuroendocrine Carcinoma
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
5.9.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma*
5.9.4. Sex- Specific Cases of the Neuroendocrine Carcinoma*
5.9.5. Diagnosed Cases of the Neuroendocrine Carcinoma
6. Unmet Needs of the Neuroendocrine Carcinoma
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM
Table 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Neuroendocrine Carcinoma in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States (2016-2028)*
Table 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France (2016-2028)
Table 12: Sub-Type Specific cases of the Neuroendocrine Carcinoma in France (2016-2028) *
Table 13: Sex- Specific Cases of the Neuroendocrine Carcinoma in France (2016-2028) *
Table 14: Diagnosed Cases of the Neuroendocrine Carcinoma in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Neuroendocrine Carcinoma in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK (2016-2028) *
Table 26: Diagnosed Cases of the Neuroendocrine Carcinoma in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

List of Figures

 

Figure 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM
Figure 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Neuroendocrine Carcinoma in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Neuroendocrine Carcinoma in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Neuroendocrine Carcinoma in France (2016-2028) *
Figure 14: Diagnosed Cases of the Neuroendocrine Carcinoma in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Neuroendocrine Carcinoma in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Neuroendocrine Carcinoma in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

China Anti inflammatory Therapeutics Market Report Forecast 2021 2027
China Anti-inflammatory Therapeutics Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-4J2573
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

China Anti tumor Drug Market Report Forecast 2021 2027
China Anti-tumor Drug Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-27N2168
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

China Asparaginase Market Report Forecast 2021 2027
China Asparaginase Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-9I393
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart